Evidence map›Paper›PMID 28818083›Full record

ArticleMicrobial cell factories2017

Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti.

Amelie Beckmann, Stephan Hüttel, Viktoria Schmitt, Rolf Müller, Marc Stadler

Abstract read
In one paragraph

Article in Microbial cell factories, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amelie BeckmannDepartment of Microbial Drugs, Helmholtz Centre for Infection Research, Brunswick, Germany.
Stephan HüttelDepartment of Microbial Drugs, Helmholtz Centre for Infection Research, Brunswick, Germany.
Viktoria SchmittHelmholtz-Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Dept. Pharmaceutical Biotechnology of Saarland University, Saarbrücken, Germany.
Rolf MüllerHelmholtz-Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Dept. Pharmaceutical Biotechnology of Saarland University, Saarbrücken, Germany.
Marc StadlerDepartment of Microbial Drugs, Helmholtz Centre for Infection Research, Brunswick, Germany. marc.stadler@helmholtz-hzi.de.ORCID http://orcid.org/0000-0002-7284-8671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class.

resultsProduction of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L

conclusionReproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules.

Indexed as

Anti-Bacterial AgentsBacteroidetesCarbon DioxideEscherichia coliGlucoseMacrolidesMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsStereoisomerismAnti-Bacterial AgentsCarbon Dioxideelansolid C1GlucoseMacrolidesAntibacterialsAntibiotic resistanceBioprocess optimizationMRSASecondary metabolites

Identifiers

PMID28818083
PMCPMC5561589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.